Chen F, An B, An WC, Fu G, Huang W, Yan HX. Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report. World J Diabetes 2025; 16(1): 99135 [DOI: 10.4239/wjd.v16.i1.99135]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jan 15, 2025; 16(1): 99135 Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.99135
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report
Fang Chen, Bo An, Wen-Cheng An, Gang Fu, Wei Huang, Hui-Xian Yan
Fang Chen, Bo An, Wen-Cheng An, Wei Huang, Hui-Xian Yan, Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China
Gang Fu, Department of Nephrology, Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing 100080, China
Author contributions: Chen F, An B, An WC, Huang W and Yan HX designed the research study; Chen F, An B and Yan HX performed the research, analyzed the data and wrote the manuscript; Chen F, Fu G and Yan HX participated in the revision of the manuscript; All authors have read and approved the final manuscript.
Informed consent statement: Informed consent was given by the patient.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: July 15, 2024 Revised: September 17, 2024 Accepted: November 5, 2024 Published online: January 15, 2025 Processing time: 137 Days and 13.9 Hours
Abstract
BACKGROUND
Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.
CASE SUMMARY
This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes (T2DM) who had struggled to control her blood sugar for more than a year. She had a history of high blood pressure for 30 years, had undergone continuous ambulatory peritoneal dialysis for more than two years, was 163 cm tall, weighed 77 kg, and had a body mass index of 28.98 kg/m2. Despite intensive insulin therapy at a daily dose of 150 units, adding Dorzagliatin at a dosage of 75 mg orally twice daily led to immediate blood sugar improvement and a gradual reduction in insulin dosage. After one month of follow-up, the fasting plasma glucose was 6-8 mmol/L, and the 2-hour postprandial glucose was 8-12 mmol/L.
CONCLUSION
To our knowledge, this report is the first to use Dorzagliatin to treat type 2 diabetes peritoneal dialysis patients with challenging glucose control. Dorzagliatin, a novel glucokinase activator primarily metabolized by the liver, exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease. It has a high plasma protein binding rate and may not be cleared by peritoneal dialysis, potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.
Core Tip: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients. To our knowledge, this report is the first to use Dorzagliatin in the treatment of type 2 diabetes peritoneal dialysis patients with challenging glucose control. Dorzagliatin, a novel glucokinase activator primarily metabolized by the liver, exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease, has a high plasma protein binding rate, and may not be cleared by peritoneal dialysis, potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.
